Don't count on it. I think they would be required to reveal the results of the trial once the results were in. It's possible that the analysis is far enough along so that they can tweak the completion date so that it coincides with the presentation, but I don't think they can sit on the results for any length of time.
I expect nothing but further promisory notes of the "real soon" variety. I'm grateful that I'm not the one required to give the presentation; it's the stuff of anxiety dreams.
What I really want to find out about is the status of the IND. The longer that drags on, the more worried I am that there are problems of some kind with the compound, either pertaining to stability or toxicology. If they can't get a low-impact approved for chronic use, corx is toast.
Market Data 
Markets 
AI
